Skip to content

Effect of Radiofrequency in Women With Chronic Pelvic Pain With an Associated Myofascial Syndrome Versus Myofascial Therapy and no Treatment

Effect of Radiofrequency in Women With Chronic Pelvic Pain With an Associated Myofascial Syndrome Versus Myofascial Therapy and no Treatment: a Randomized Clinical Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06908200
Enrollment
80
Registered
2025-04-03
Start date
2022-05-10
Completion date
2025-06-15
Last updated
2025-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pelvic Pain

Keywords

chronic pelvic pain, myofascial syndrome, radiofrequency, manual therapy

Brief summary

A randomised clinical trial is being conducted in the Gynecology Department of the Hospital Clinic de Barcelona in women presenting chronic pelvic pain syndrome due to a myofascial cause which is over a 4 score in the VAS scale and not related to an obstetric injury. This study presents 4 groups; two groups receive 8 radiofrequency sessions, one group receives 8 sessions of myofascial release therapy (MRT) and the last group receives no treatment at all (NT). The two RF groups have been divided into a RF intervention group (RFIG) and a RF control group (RFCG) which receives sham treatment. The RF groups are double-blinded. Other than RF, both groups perform daily Thiele massage at home. The sessions last for 20 minutes and take place once a week during 8 weeks. The main variable evaluated is the level of pain during the muscular assessment carried out by an expert pelvic floor physical therapist using the Verbal numeric Scale in the first session and at the end of the 8 sessions. Secondary variables are: sexual function (throughout FSFI questionnaire), pain catastrophizing (ECD), quality of life (EQ5D), anxiety and depression (HADS), central sensitization (CSI) as well as other pelvic floor dysfunction symptoms (PFDI).

Interventions

DEVICERadiofrequency therapy

Radiofrequency or myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home

OTHERmyofascial manual therapy

Myofascial manual therapy sessions including the abdominal region, the vulva and pelvic floor tissue and Thiele massage done daily by the patient at home

Sponsors

Hospital Clinic of Barcelona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

included women who were: * At least 18 years of age * Presenting with pelvic pain persisting for at least 6 months * Diagnosed with myofascial syndrome of the pelvic floor muscles (PFM) by a specialist based on physical assessment * Presenting with pelvic pain intensity greater than 4 on the Visual Analog Scale (VAS) in the last 3 months * Agreed to sign the informed consent form.

Exclusion criteria

included the following: * Patients who were pregnant * Postpartum patients who had given birth within the last year * Patients with a history of vulvovaginal pathology * Contraindications for the use of radiofrequency: metal implants or active infection * Patients with a history of pelvic cancer, including those who had undergone chemotherapy, radiotherapy, and/or brachytherapy.

Design outcomes

Primary

MeasureTime frameDescription
Pain Level8 weeksPain Level using the Verbal Numeric Scale (VNS). The scores go from 0 (lowest) to 10 (highest)

Secondary

MeasureTime frameDescription
Sexual function8 weeksSexual function using the female sexual function index. The score ranges from 2 (severe) to 36 (no sexual disfunction)
Quality of life (QoL)8 weeksQuality of life using the EuroQuality of life-5Dimensions (EQ5D. Ranges from -0.59 (lowest QoL) and 1 (highest)
Pain catastrophizing8 weeksUsing the pain catastrophizing scale (PCS).Ranges from 0 to 52 where higher scores indicate a greater degree of pain catastrophizing. A total score of \>30 represents a clinically significant level of pain catastrophization
Anxiety and depression8 weeksAnxiety and depression using the Hospital Anxiety and depression Scale (HADS). Generally, scores of 0 to 7 on this questionnaire are considered to be normal, scores of 8 to 10 indicate mild symptoms, 11 to 14 indicate moderate symptoms, and 15 to 21 indicate severe symptoms
Central sensitization8 weeksUsing the central sensitization index (CSI). Ranging from 0-100, \>40 is the cutoff for pain sensitization

Countries

Spain

Contacts

Primary ContactCarla Box, PT, MSc
cebox@clinic.cat+34932275300

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026